Biogen Inc. $BIIB Shares Acquired by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. increased its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1,540.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 716,848 shares of the biotechnology company’s stock after purchasing an additional 673,149 shares during the quarter. Biogen accounts for about 0.8% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 19th largest holding. Resona Asset Management Co. Ltd.’s holdings in Biogen were worth $161,922,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in BIIB. BlackRock Inc. bought a new position in shares of Biogen in the 2nd quarter valued at about $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen during the 2nd quarter valued at $3,274,304,000. Public Sector Pension Investment Board lifted its stake in shares of Biogen by 10,085.8% in the 3rd quarter. Public Sector Pension Investment Board now owns 2,466,095 shares of the biotechnology company’s stock valued at $557,042,000 after purchasing an additional 2,441,884 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Biogen by 1,524.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after purchasing an additional 2,041,161 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Biogen in the 2nd quarter worth $322,640,000. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on BIIB shares. HC Wainwright set a $270.00 price target on Biogen and gave the company a “buy” rating in a research note on Thursday. Royal Bank Of Canada increased their price target on shares of Biogen from $256.00 to $272.00 and gave the company an “outperform” rating in a research report on Thursday, October 29th. Wolfe Research raised shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a research note on Thursday, August 13th. TD Cowen boosted their price objective on shares of Biogen from $250.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Wells Fargo & Company upped their target price on shares of Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $255.45.

Read Our Latest Stock Analysis on Biogen

Biogen News Summary

These are some of the BIIB news items that stood out recently:

  • Positive Sentiment: Biogen and Eisai reported that lecanemab slowed clinical decline over 18 months in an analysis of early Alzheimer’s patients with ?-synuclein co-pathology. The subgroup results were exploratory and post hoc, but add supportive evidence for LEQEMBI’s potential reach. Article
  • Positive Sentiment: Coverage also highlighted three-year real-world LEQEMBI data reporting slower Alzheimer’s progression, another potential support for the drug’s commercial prospects. Article
  • Neutral Sentiment: Analyst commentary is mixed overall: one report says analysts remain moderately upbeat and notes BIIB has outpaced broad benchmarks over the past year, while another says Alzheimer’s progress and M&A-related growth expectations may already be reflected in the valuation. Analyst outlook Rating downgrade

Biogen Stock Performance

Shares of BIIB stock opened at $249.59 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The company has a market capitalization of $36.89 billion, a P/E ratio of 106.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.10. The company’s 50 day moving average price is $236.83 and its two-hundred day moving average price is $206.86. Biogen Inc. has a 52 week low of $160.36 and a 52 week high of $261.00.

Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.81 earnings per share. On average, analysts expect that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.

About Biogen

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

See Also

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.